Breast Removal — Cost, Top Hospitals & Success Rates | MyMedicPlus

Mastectomy is the surgical removal of all or nearly all breast tissue from one breast (unilateral) or both breasts (bilateral), performed as a therapeutic treatment for breast cancer or as a risk-reduction (prophylactic) measure in women at very high genetic risk. It is one of the most significant surgeries in oncology and has evolved considerably — from the disfiguring radical mastectomy of the early 20th century, which removed the breast, underlying chest muscles, and axillary lymph nodes en bloc, to the modern skin-sparing and nipple-sparing mastectomies that remove breast tissue while preserving the skin envelope and, in selected cases, the nipple-areolar complex, facilitating excellent reconstructive outcomes.

The procedure is performed under general anaesthesia, typically takes two to three hours for mastectomy alone, and may extend to four to eight hours when immediate reconstruction is performed simultaneously. Hospital stay is two to five days depending on whether reconstruction is performed. The surgeon removes the entire breast parenchyma, often including the nipple-areolar complex (except in nipple-sparing techniques), through an elliptical or curved incision and simultaneously addresses the axillary lymph nodes via sentinel lymph node biopsy or axillary lymph node dissection based on preoperative nodal staging.

Post-mastectomy radiotherapy may be recommended for patients with high-risk features (four or more positive lymph nodes, involved margins, large tumours, or inflammatory breast cancer) and significantly influences reconstruction planning. The decision between mastectomy and breast-conserving surgery (lumpectomy) is made collaboratively between patient and surgeon, based on tumour characteristics, patient anatomy, treatment preferences, and access to radiotherapy.

Therapeutic mastectomy is performed for breast cancer that is not amenable to breast-conserving surgery — including large tumours relative to breast volume, multifocal or multicentric malignancy (cancer in multiple areas of the same breast), inflammatory breast cancer (after neoadjuvant chemotherapy), locally recurrent breast cancer in a previously irradiated breast, and patient preference for mastectomy over breast conservation. Paget disease of the nipple involving the nipple-areolar complex requires mastectomy when the underlying tumour is multicentric.

Prophylactic mastectomy is performed for risk reduction in women with documented very high lifetime breast cancer risk. BRCA1 mutation carriers have a 60 to 80% lifetime risk; BRCA2 carriers approximately 45 to 65%. Bilateral prophylactic mastectomy reduces this risk by approximately 90 to 95%. High-risk women who have been treated for cancer in one breast may undergo contralateral prophylactic mastectomy simultaneously to reduce their risk in the unaffected breast. Men with BRCA2 mutations and gynaecomastia causing significant symptoms or with identified DCIS may also undergo mastectomy.

All patients with breast cancer that is not surgically manageable by breast-conserving means are candidates for mastectomy. Patients with confirmed BRCA1 or BRCA2 pathogenic variants who have undergone genetic counselling and have made an informed decision for prophylactic mastectomy are candidates for risk-reducing surgery. Ideal surgical candidates have sufficient medical fitness to tolerate general anaesthesia and the planned procedure. Immediate reconstruction candidacy depends on additional factors including the likely need for post-mastectomy radiotherapy and skin quality.

The decision to undergo mastectomy versus breast-conserving surgery is not solely based on oncological factors — patient anxiety, preference for avoiding radiation (long-term commitment of daily treatment for three to five weeks), concerns about local recurrence, and desire for contralateral symmetry all legitimately influence the decision. Women who choose mastectomy for personal rather than purely oncological reasons should receive full, non-judgmental counselling including realistic discussion of equivalent survival outcomes with breast-conserving surgery for appropriate tumours.

Total (simple) mastectomy removes all breast tissue and the nipple-areolar complex through an elliptical incision, leaving a horizontal scar across the chest wall. This is the standard technique and provides the flat chest wall favoured by some patients who choose not to reconstruct. Modified radical mastectomy additionally removes the axillary lymph nodes (levels I and II) through the same incision, used when axillary dissection is required. It preserves the chest muscles (pectoralis major and minor), unlike the now-obsolete radical mastectomy.

Skin-sparing mastectomy removes the breast tissue and nipple-areolar complex through a periareolar incision, preserving the majority of the breast skin envelope to facilitate implant-based or autologous reconstruction with superior cosmetic outcomes. Nipple-sparing mastectomy (NSM) additionally preserves the nipple-areolar complex, with breast tissue beneath the nipple removed and sent for frozen section to exclude tumour involvement. NSM is oncologically safe for tumours not centrally located, not involving the nipple skin, and with adequate distance from the nipple (typically more than 2 cm). NSM provides the best cosmetic outcome of any mastectomy type when combined with immediate reconstruction. Robotic-assisted nipple-sparing mastectomy is an emerging technique using remote-access endoscopic tools to perform the procedure through small axillary or inframammary incisions, reducing visible scarring.

For therapeutic mastectomy in breast cancer treatment, local recurrence rates are lower than with breast-conserving surgery plus radiotherapy for selected high-risk features, though long-term cancer-specific survival is equivalent in the majority of appropriately selected cases. For patients with BRCA1/2 mutations, prophylactic bilateral mastectomy reduces breast cancer incidence by 90 to 95%, with studies showing significantly improved overall survival compared with surveillance alone in high-risk women.

Modern mastectomy techniques, particularly nipple-sparing mastectomy combined with immediate reconstruction, achieve excellent cosmetic outcomes with high patient satisfaction. Women who undergo immediate breast reconstruction have significantly better body image, psychosocial wellbeing, and sexual self-confidence than women who undergo mastectomy without reconstruction. The psychological benefit of eliminating the constant cancer anxiety associated with BRCA carrier status is a major reported benefit of prophylactic mastectomy, with studies showing significant improvements in cancer-specific worry scores after surgery.

General surgical risks of mastectomy include haematoma (2 to 5%), seroma — fluid accumulation under the wound (20 to 30%, may require repeated aspiration), wound infection (2 to 4%), and wound healing problems. Sensory changes in the chest wall, upper arm, and axilla are common after axillary surgery and mastectomy; numbness, tingling, and phantom breast sensations affect 20 to 40% of patients and are often permanent. Lymphoedema of the arm — swelling due to disrupted lymphatic drainage — affects 3 to 5% after sentinel lymph node biopsy and 20 to 25% after full axillary node dissection.

Nipple-sparing mastectomy carries additional risks of nipple-areolar complex necrosis (2 to 8%) due to compromised blood supply after complete undermining — smoking and large ptotic breasts significantly increase this risk. When immediate reconstruction is combined with mastectomy, reconstruction-specific complications are added to the mastectomy risks. Post-mastectomy radiotherapy, if required, significantly increases implant-based reconstruction complication rates. Psychological challenges after mastectomy including body dysmorphia, relationship difficulties, and depression are under-recognised and should be proactively addressed with psychological support.

Post-operative hospital stay is typically two to three days for mastectomy alone or three to five days with immediate reconstruction. Wound drains are placed at the time of surgery and removed when output is less than 30 to 50 ml per 24 hours, usually within three to seven days. A soft supportive garment or post-mastectomy bra is worn for four to six weeks. Arm mobility exercises are commenced from day one to prevent stiffness. Full arm movement is usually restored within two to four weeks.

Return to sedentary work is typically possible within two to four weeks. Strenuous exercise and heavy lifting are restricted for six to eight weeks. Cancer surveillance after therapeutic mastectomy includes clinical examination every three to six months for the first three years, then annually, plus annual mammography of the remaining contralateral breast (if applicable). HER2-positive patients receive echocardiographic monitoring during trastuzumab therapy. BRCA-positive patients who have undergone prophylactic mastectomy continue annual breast MRI surveillance of any retained native breast tissue. Genetic counselling for family members is recommended.

Mastectomy in the United States costs $15,000 to $30,000 for the procedure alone; bilateral mastectomy with immediate implant reconstruction may cost $30,000 to $60,000 or more. The Women's Health and Cancer Rights Act mandates insurance coverage for mastectomy and reconstruction for breast cancer patients in the US. In the UK, NHS covers all medically indicated mastectomy and post-mastectomy reconstruction, though wait times and technique availability may vary.

For international self-pay patients or those seeking surgery in world-class centres abroad, JCI-accredited cancer hospitals in India and Thailand offer mastectomy with immediate reconstruction at significantly reduced costs. A unilateral mastectomy with immediate implant reconstruction at a leading centre in India costs $4,000 to $8,000; bilateral mastectomy with reconstruction is $7,000 to $15,000. Thai centres charge $8,000 to $18,000 for comparable procedures. Medical tourists benefit from savings of 50 to 70% while receiving care from oncoplastic surgeons trained at leading international institutions.

For appropriately selected breast cancers, breast-conserving surgery (lumpectomy or wide local excision) combined with post-operative radiotherapy achieves equivalent cancer-specific survival to mastectomy and is the preferred alternative for patients with unifocal tumours that are small relative to breast volume. Multiple randomised controlled trials including Milan I and NSABP B-06 with over 20 years of follow-up have confirmed equivalent survival outcomes, and breast-conserving surgery is the standard of care for eligible patients who can access radiotherapy.

For BRCA carriers who wish to avoid surgery, enhanced surveillance (annual MRI plus mammography, clinical examination every six months) is an alternative to prophylactic mastectomy. Chemoprevention with tamoxifen or aromatase inhibitors reduces breast cancer incidence by approximately 30 to 40% in high-risk women but does not achieve the 90 to 95% risk reduction of mastectomy. Surveillance, rather than surgery, may be preferred by younger BRCA carriers who wish to complete childbearing first, with mastectomy deferred until an appropriate time.